Neurocrine Biosciences (NASDAQ:NBIX) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Wedbush currently has a $152.00 target price on the stock. NBIX has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price target on shares […]

Related Keywords

Los Angeles ,California ,United States ,Eric Benevich ,Matt Abernethy ,Neurocrine Biosciences ,Westfield Capital Management Co ,Barclays ,Norges Bank ,Cantor Fitzgerald ,Securities Exchange Commission ,Neurocrine Biosciences Inc ,Canaccord Genuity Group ,Jacobs Levy Equity Management Inc ,Los Angeles Capital Management ,Jpmorgan Chase Co ,Free Report ,Genuity Group ,Moderate Buy ,Biosciences Stock Down ,Get Free Report ,Exchange Commission ,Point Capital ,Angeles Capital Management ,Capital Management ,Jacobs Levy Equity Management ,Levy Equity Management ,Neurocrine Biosciences Daily ,